Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from IM Cannabis Corp ( (IMCC) ) is now available.
IM Cannabis Corp reported its financial results for the third quarter of 2025, revealing consistent revenue of $13.9 million compared to the same period in 2024. However, the company experienced a 13% decrease in gross profit and gross margin, attributed to a $3.1 million impairment of goodwill and intangible assets. The company is undergoing a transition year, with potential regulatory changes in Germany that could impact sales. Despite these challenges, IM Cannabis is exploring new business activities to support long-term growth and value creation.
The most recent analyst rating on (IMCC) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on IM Cannabis Corp stock, see the IMCC Stock Forecast page.
Spark’s Take on IMCC Stock
According to Spark, TipRanks’ AI Analyst, IMCC is a Neutral.
IM Cannabis Corp’s stock score is primarily impacted by its poor financial performance, characterized by ongoing losses, rising leverage, and negative cash flows. Technical analysis also indicates a bearish trend, with the stock trading below key moving averages and weak momentum indicators. Valuation metrics are unfavorable due to a negative P/E ratio and lack of dividend yield.
To see Spark’s full report on IMCC stock, click here.
More about IM Cannabis Corp
IM Cannabis Corp is an international medical cannabis company. It focuses on the production and distribution of medical cannabis products, with operations in key markets such as Canada, Israel, and Germany.
Average Trading Volume: 449,282
Technical Sentiment Signal: Sell
Current Market Cap: $7.56M
Learn more about IMCC stock on TipRanks’ Stock Analysis page.